---
title: "genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-08-11T08:14:55+00:00"
modified: "2025-08-11T08:14:55+00:00"
date: 2025-08-11
canonical: "https://www.share-talk.com/genedrive-plc-aim-gdr-expects-revenue-to-double-as-commercial-momentum-builds/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["Antibiotic", "biological", "blood clots", "chemistry", "coronavirus", "COVID-19", "COVID19", "David Budd", "diagnostics", "GDR", "Genedrive", "Genedrive Kit", "Genedrive PLC", "Greater Manchester", "hospital", "infectious diseases", "lab testing", "Manchester", "Matthew Fowler", "molecular", "MT-RNR1 ID Kit", "NHS", "Royal Albert Edward Infirmary", "Royal Bolton Hospital", "SARS-COV-2", "Share Talk", "Stepping Hill Hospital", "Tameside General Hospital", "The Royal Oldham Hospital", "UK hospitals"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/12/Genedrive.jpg?fit=1200%2C800&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds

**Published:** August 11, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** Antibiotic, biological, blood clots, chemistry, coronavirus, COVID-19, COVID19, David Budd, diagnostics, GDR, Genedrive, Genedrive Kit, Genedrive PLC, Greater Manchester, hospital, infectious diseases, lab testing, Manchester, Matthew Fowler, molecular, MT-RNR1 ID Kit, NHS, Royal Albert Edward Infirmary, Royal Bolton Hospital, SARS-COV-2, Share Talk, Stepping Hill Hospital, Tameside General Hospital, The Royal Oldham Hospital, UK hospitals
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/12/Genedrive.jpg?fit=1200%2C800&quality=89&ssl=1)

---

**Genedrive PLC (AIM: GDR),** the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around **£1 million**, up from **£0.5 million** a year earlier.

The increase was driven by[stronger second-half sales](https://www.investegate.co.uk/announcement/rns/genedrive--gdr/trading-update/9042109) of **£0.65 million**, compared with **£0.35 million** in the first half. Overheads were stable, with a greater focus on targeted commercial activity.

The company has visibility on approximately **£0.6 million** in early income for the current financial year, supported by key developments:

-
Completion and submission of evidence to **NICE** for its Early Value Assessment, potentially unlocking wider UK adoption.

-
Scotland’s phased national rollout of two Genedrive tests from around October.

-
Launch of a 12-month rapid genotyping programme at **Manchester University NHS Foundation Trust**.

Internationally, sales in **Europe** and the **Middle East** are gaining traction, while the **US** remains a priority market. FDA regulatory work is ongoing for its MT-RNR1 and CYP2C19 test kits, with the latter’s submission expected early next year.

Cash balances stand at around **£700,000**, and the board is reviewing financing options to bolster working capital.

Genedrive welcomed planned NHS reforms in England that will expand the **NICE** appraisal pathway and introduce an ‘innovator passport’ from April 2026, aimed at accelerating uptake of medical technologies.

CEO **Dr Gino Miele** said the company’s platform delivers improved patient outcomes, productivity gains for healthcare providers, and cost savings for the NHS. He also noted increasing traction in **Italy, the Netherlands, UAE, Bahrain, Kuwait, Saudi Arabia, and Qatar**.

---

**Original URL:** https://www.share-talk.com/genedrive-plc-aim-gdr-expects-revenue-to-double-as-commercial-momentum-builds/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*